Anti-Inflammatory and Immunosuppressive Effects of the A 2A Adenosine Receptor
The production of adenosine represents a critical endogenous mechanism for regulating immune and inflammatory responses during conditions of stress, injury, or infection. Adenosine exerts predominantly protective effects through activation of four 7-transmembrane receptor subtypes termed A 1 , A 2A...
Saved in:
Published in | TheScientificWorld Vol. 11; pp. 320 - 339 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
2011
|
Online Access | Get full text |
Cover
Loading…
Summary: | The production of adenosine represents a critical endogenous mechanism for regulating immune and inflammatory responses during conditions of stress, injury, or infection. Adenosine exerts predominantly protective effects through activation of four 7-transmembrane receptor subtypes termed A
1
, A
2A
, A
2B
, and A
3
, of which the A
2A
adenosine receptor (A
2A
AR) is recognised as a major mediator of anti-inflammatory responses. The A
2A
AR is widely expressed on cells of the immune system and numerous
in vitro
studies have identified its role in suppressing key stages of the inflammatory process, including leukocyte recruitment, phagocytosis, cytokine production, and immune cell proliferation. The majority of actions produced by A
2A
AR activation appear to be mediated by cAMP, but downstream events have not yet been well characterised. In this article, we review the current evidence for the anti-inflammatory effects of the A
2A
AR in different cell types and discuss possible molecular mechanisms mediating these effects, including the potential for generalised suppression of inflammatory gene expression through inhibition of the NF-κB and JAK/STAT proinflammatory signalling pathways. We also evaluate findings from
in vivo
studies investigating the role of the A
2A
AR in different tissues in animal models of inflammatory disease and briefly discuss the potential for development of selective A
2A
AR agonists for use in the clinic to treat specific inflammatory conditions. |
---|---|
ISSN: | 1537-744X 1537-744X |
DOI: | 10.1100/tsw.2011.22 |